Articles tagged with: Carfilzomib
Results from three clinical trials involving the investigational drug filanesib were presented at the American Society of Hematology (ASH) annual meeting earlier this month.
Overall, the trial results presented at ASH confirm existing impressions of filanesib as a promising potential myeloma therapy.
Results of a Phase 2 trial of filanesib with or without low-dose dexamethasone (Decadron) show that 16 percent of …
Monday was the third day of this year’s meeting of the American Society of Hematology (ASH). The day was filled with oral presentation sessions from early in the morning until into the evening.
In the afternoon and early evening, there were six oral presentation sessions devoted solely to multiple myeloma and a number of other myeloma-related presentations scattered about the afternoon. The topics of these presentations ranged from the biology of myeloma to treatment options for newly diagnosed, relapsed and refractory, and older patients.
This ASH update highlights most of …
Yesterday was the second day of the American Society of Hematology’s (ASH) annual meeting, which is being held in New Orleans.
As on Saturday, myeloma-related presentations were once again made during several sessions throughout the day.
Experts who missed the education session on Saturday had the opportunity to attend the session again early Sunday morning.
One myeloma study was presented during the plenary session in the early afternoon. The six presentations in this session covered all blood cancers and are considered particularly important studies.
The myeloma study included in this …
This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in New Orleans.
Myeloma-related presentations were made during several sessions yesterday.
Two sessions were designed to better educate physicians about multiple myeloma and how to treat the disease.
The key myeloma-related research presented yesterday was made public during a poster session in the evening about the biology of myeloma as well as preclinical and clinical studies testing new and existing treatments for myeloma.
During the session, research results were made available for review by meeting attendees in …
Results from a recent Phase 2 trial indicate that the combination of Kyprolis, Revlimid, and dexamethasone is effective in relapsed multiple myeloma patients.
Specifically, the results show that 77 percent of patients responded to the treatment. The investigators point out the responses seen in the trial were rapid (median time to response was one month) and robust (median duration of response was 22 months).
According to the investigators, the results are particularly encouraging because one-quarter of the patients were refractory (resistant) to Velcade (bortezomib) and almost half were …